Hepatitis B antibody in conventional gamma-globulin

Area of Science:

• Immunology
• Hepatology
• Public Health

Background:

• Conventional gamma-globulin is a key treatment for hepatitis B.
• Antibody (anti-HBs) titers in gamma-globulin have varied historically.
• Hepatitis B surface antigen (HBs Ag) presence in plasma pools is a concern.

Purpose of the Study:

• To investigate the increasing antibody (anti-HBs) titers in recent gamma-globulin lots.
• To compare current anti-HBs titers with historical lots and efficacy data.
• To understand the impact of donor screening on antibody levels.

Main Methods:

• Analysis of antibody (anti-HBs) titers in gamma-globulin lots from different collection periods.
• Review of historical data on hepatitis B incidence and plasma pool composition.
• Comparison of current Massachusetts gamma-globulin titers with established efficacy benchmarks.

Main Results:

• Recent gamma-globulin lots exhibit significantly higher anti-HBs titers compared to pre-1970 lots.
• Anti-HBs titers have steadily increased since mandatory HBs Ag screening began in 1971.
• Current Massachusetts gamma-globulin anti-HBs titers meet or exceed those effective in pre-exposure prophylaxis studies.

Conclusions:

• Enhanced donor screening for hepatitis B surface antigen (HBs Ag) has improved gamma-globulin quality.
• Increased antibody (anti-HBs) levels in gamma-globulin enhance its efficacy for hepatitis B prevention.
• Current production methods yield gamma-globulin with robust protective antibody titers.